| Literature DB >> 32617075 |
Christina K Weisheit1, Alexandra Klüners1, Lennart Wild1, Alexandra Casalter1, Stefanie Heilmann-Heimbach2, Sugirthan Sivalingam2, Jan L Kleiner1, Stefan F Ehrentraut1, Andreas Hoeft1, Stilla Frede1, Heidi Ehrentraut1.
Abstract
Sepsis is associated with a strong inflammatory reaction triggering a complex and prolonged immune response. Septic patients have been shown to develop sustained immunosuppression due to a reduced responsiveness of leukocytes to pathogens. Changes in cellular metabolism of leukocytes have been linked to this phenomenon and contribute to the ongoing immunological derangement. However, the underlying mechanisms of these phenomena are incompletely understood. In cell culture models, we mimicked LPS tolerance conditions to provide evidence that epigenetic modifications account for monocyte metabolic changes which cause immune paralysis in restimulated septic monocytes. In detail, we observed differential methylation of CpG sites related to metabolic activity in human PBMCs 18 h after septic challenge. The examination of changes in immune function and metabolic pathways was performed in LPS-tolerized monocytic THP-1 cells. Passaged THP-1 cells, inheriting initial LPS challenge, presented with dysregulation of cytokine expression and oxygen consumption for up to 7 days after the initial LPS treatment. Proinflammatory cytokine concentrations of TNFα and IL1β were significantly suppressed following a second LPS challenge (p < 0.001) on day 7 after first LPS stimulation. However, the analysis of cellular metabolism did not reveal any noteworthy alterations between tolerant and nontolerant THP-1 monocytes. No quantitative differences in ATP and NADH synthesis or participating enzymes of energy metabolism occurred. Our data demonstrate that the function and epigenetic modifications of septic and tolerized monocytes can be examined in vitro with the help of our LPS model. Changes in CpG site methylation and monocyte function point to a correlation between epigenetic modification in metabolic pathways and reduced monocyte function under postseptic conditions.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32617075 PMCID: PMC7306843 DOI: 10.1155/2020/8294342
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Study design. Timeline of PBMC and THP-1 cultivation, LPS treatment, and sampling.
Figure 2Induction of innate immunotolerance in human PBMCs. PBMCs (106 cells/ml) were isolated from whole blood (n = 4 individual donors) and stimulated for 18 h with 10 ng LPS/ml or PBS. Cytokine transcription (a) and secretion (b) were detected upon additional 3 h exposure to LPS or PBS (100 ng/ml). Mean ± SD; n = 4; ∗p < 0.05; ∗∗p < 0.01.
Figure 3Methylation level of significant CpG sites. Methylome analysis of DNA was performed on PBMCs derived from healthy human donors (n = 4).
Upon 18 h LPS tolerization (10 ng LPS/ml media or PBS as control, 106 cells/ml), methylome analysis of DNA derived from healthy human PBMC donors (n = 4) was performed and KEGG pathway results are presented.
| Top KEGG pathways |
| DE | P.DE | FDR | ||
|---|---|---|---|---|---|---|
| 1 | path:hsa01100 | Metabolic pathways | 1252 | 870 | 6,27 | 2,01 |
| 2 | path:hsa05200 | Pathways in cancer | 394 | 316 | 1,20 | 1,93 |
| 3 | path:hsa05165 | Human papillomavirus infection | 318 | 244 | 1,79 | 1,91 |
| 4 | path:hsa04151 | PI3K-Akt signaling pathway | 339 | 243 | 9,24 | 7,39 |
| 5 | path:hsa04010 | MAPK signaling pathway | 255 | 197 | 5,27 | 3,37 |
| 6 | path:hsa05166 | HTLV-I infection | 252 | 192 | 1,05 | 5,63 |
| 7 | path:hsa04360 | Axon guidance | 174 | 151 | 2,22 | 1,01 |
| 8 | path:hsa04144 | Endocytosis | 244 | 186 | 4,18 | 1,67 |
| 9 | path:hsa04015 | Rap1 signaling pathway | 210 | 167 | 1,86 | 6,61 |
| 10 | path:hsa04014 | Ras signaling pathway | 226 | 173 | 2,24 | 7,15 |
| 11 | path:hsa05169 | Epstein-Barr virus infection | 197 | 156 | 3,43 | 9,97 |
| 12 | path:hsa04510 | Focal adhesion | 198 | 159 | 4,35 | 1,16 |
| 13 | path:hsa05205 | Proteoglycans in cancer | 203 | 157 | 1,11 | 2,74 |
| 14 | path:hsa04810 | Regulation of actin cytoskeleton | 211 | 160 | 8,19 | 1,87 |
| 15 | path:hsa05202 | Transcriptional misregulation in cancer | 181 | 141 | 7,12 | 1,52 |
| 16 | path:hsa05203 | Viral carcinogenesis | 198 | 149 | 1,27 | 2,53 |
| 17 | path:hsa05167 | Kaposi's sarcoma-associated herpesvirus infection | 186 | 140 | 2,96 | 5,58 |
| 18 | path:hsa04022 | cGMP-PKG signaling pathway | 162 | 132 | 1,17 | 2,09 |
| 19 | path:hsa05016 | Huntington's disease | 186 | 140 | 1,65 | 2,79 |
| 20 | path:hsa04141 | Protein processing in endoplasmic reticulum | 165 | 131 | 1,85 | 2,96 |
KEGG pathway: code from Kyoto Encyclopedia of Genes and Genomes; N: number of KEGG pathway-related CpG sites contained in array; DE: number of differentially methylated CpG sites; P.DE: adjusted differential methylation p value; FDR: false discovery rate.
Figure 4LPS-tolerized (1 μg/ml) THP-1 monocytes (106 cells/ml) demonstrate sustained cytokine mRNA and protein alterations upon 6 h LPS restimulation (1 μg/ml) compared to previously untreated cells. mRNA transcription (a) and protein secretion (b) of TNFα and IL-1β were measured at different time points after 48 h preincubation followed by resting durations of 0 d (≙ passage (P)1), 2 d (≙ P2), and 5 d (≙ P3) prior to repeated LPS exposure. Mean ± SD; n = 6.
Figure 5Immunotolerant THP-1 monocytes demonstrate altered metabolism after LPS pretreatment. Cells were stimulated with LPS (1 μg/ml) for 48 h and rested for 5 d after LPS removal. Afterwards, they were challenged with LPS (1 μg/ml) or PBS as indicated. (a) demonstrates a representative measurement of LPS-tolerized and nontolerized cells over 20 h. Oxygen rates (b, c) of monocytes left untreated or preincubated with LPS. Pooled data from (n = 9) independent measurements each with 4 technical replicates. MTT assay (b, n = 3-5), LDH activity (c, n = 4), lactate secretion (d, n = 7), and NAD+/NADH (e, n = 8) levels were detected. Mean ± SD; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.